Management of Chronic Kidney Disease Stages 1–3
Conclusions: Screening and Monitoring
Based on treatment-related findings of randomized controlled trials and additional indirect data—including high chronic kidney disease (CKD) prevalence, low CKD recognition, and limited CKD monitoring in usual care; uncertain sensitivity of screening and monitoring measures for CKD; and insufficient evidence on CKD screening and monitoring harms—the overall benefits of CKD screening and monitoring are unclear. The likelihood of benefit, if present, appears to be greater in specific subgroups. Younger patients and those without diabetes, hypertension, cardiovascular disease, or obesity are the least likely to benefit from CKD screening.
- Fink HA, Ishani A, Taylor BC, et al. Chronic Kidney Disease Stages 1–3: Screening, Monitoring, and Treatment. Comparative Effectiveness Review No. 37 (Prepared by the Minnesota Evidence-based Practice Center under Contract No. HHSA 290-2007-10064-I). Rockville, MD: Agency for Healthcare Research and Quality; January 2012. AHRQ Publication No. 11(12)-EHC075-EF. Available at www.effectivehealthcare.ahrq.gov/ckd.cfm.
Your slide tray is being processed.